title: Endoscopic ultrasound-guided transmural drainage for pancreatic fistula or pancreatic duct dilation after pancreatic surgery.
abstract: BACKGROUND
  Endoscopic ultrasound (EUS)-guided drainage is widely used to manage pancreatic pseudocysts. Several studies have reported the use of EUS-guided drainage for pancreatic fistula and stasis of pancreatic juice caused by stricture of the pancreatic duct after pancreatic resection.
  
  
  METHODS
  At the authors' hospital, 262 patients underwent surgery involving pancreatic resection from April 2005 to March 2010. In 90 of these patients (34%), a grade B or C postoperative pancreatic fistula developed that required additional treatment. The authors performed EUS-guided transmural drainage (EUS-TD) for six patients (2.1%) with a pancreatic fistula or dilation of the main pancreatic duct visible by EUS. Percutaneous drainage was provided for 18 patients (6.8%). The success rates for EUS-TD and percutaneous drainage were compared in a retrospective analysis.
  
  
  RESULTS
  In all six cases, EUS-TD was performed successfully without complications. Five of the six patients were successfully treated with only one trial of EUS-TD. The final technical success rate was 100% for both EUS-TD and percutaneous drainage. Both the short- and long-term clinical success rates for EUS-TD were 100% and those for percutaneous drainage were 61.1 and 83%, respectively. The differences in these rates were not significant (short-term success, P = 0.091 vs. long-term success, P = 0.403). However, the time to clinical success was significantly shorter with EUS-TD (5.8 days) than with percutaneous drainage (30.4 days; P = 0.0013) in the current series.
  
  
  CONCLUSIONS
  The EUS-TD approach appears to be a safe and technically feasible alternative to percutaneous drainage and may be considered as first-line therapy for pancreatic fistulas visible by EUS.
authors.affiliation: Department of Gastroenterology, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan.
authors.forename: Manabu
authors.initials: M
authors.lastname: Onodera
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kawakami
authors.forename: Masaki
authors.initials: M
authors.lastname: Kuwatani
authors.forename: Taiki
authors.initials: T
authors.lastname: Kudo
authors.forename: Shin
authors.initials: S
authors.lastname: Haba
authors.forename: Yoko
authors.initials: Y
authors.lastname: Abe
authors.forename: Shuhei
authors.initials: S
authors.lastname: Kawahata
authors.forename: Kazunori
authors.initials: K
authors.lastname: Eto
authors.forename: Yuya
authors.initials: Y
authors.lastname: Nasu
authors.forename: Eiichi
authors.initials: E
authors.lastname: Tanaka
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hirano
authors.forename: Masahiro
authors.initials: M
authors.lastname: Asaka
mesh_terms: D000368:Aged; D001650:Bile Duct Neoplasms / Q000473:pathology / Q000601:surgery*; D004108:Dilatation, Pathologic / Q000209:etiology; D004322:Drainage / Q000379:methods; D019160:Endosonography / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010183:Pancreatic Ducts; D010185:Pancreatic Fistula / Q000628:therapy*; D010190:Pancreatic Neoplasms / Q000473:pathology / Q000601:surgery*; D011183:Postoperative Complications / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome